AAPL294.01-0.29 (-0.10%) ▼|ABBV234.85+0.09 (+0.04%) ▲|ABT90.36-0.18 (-0.19%) ▼|ACN129.29+2.28 (+1.80%) ▲|ADBE197.28-0.15 (-0.08%) ▼|AMAT584.38-1.51 (-0.26%) ▼|AMD516.50-3.35 (-0.64%) ▼|AMGN351.92+4.91 (+1.41%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN234.33+0.22 (+0.09%) ▲|AVGO380.80+0.65 (+0.17%) ▲|AXP343.31+5.53 (+1.64%) ▲|BA220.30+3.59 (+1.66%) ▲|BAC57.84-0.08 (-0.13%) ▼|BKNG180.92+11.98 (+7.09%) ▲|BLK982.66-32.67 (-3.22%) ▼|BMY55.23-0.31 (-0.55%) ▼|BNY143.88-3.41 (-2.32%) ▼|BRK-B495.33+2.52 (+0.51%) ▲|C144.27-0.70 (-0.48%) ▼|CAT992.01+7.77 (+0.79%) ▲|CL91.81+0.38 (+0.42%) ▲|CMCSA22.64-0.17 (-0.72%) ▼|COF200.99+3.18 (+1.61%) ▲|COP107.42-2.56 (-2.32%) ▼|COST960.78+3.10 (+0.32%) ▲|CRM152.74-0.68 (-0.44%) ▼|CSCO119.86-1.29 (-1.06%) ▼|CVS102.32+0.75 (+0.74%) ▲|CVX171.96-4.02 (-2.28%) ▼|DE604.26+12.32 (+2.08%) ▲|DHR188.08+9.11 (+5.09%) ▲|DIS101.47-2.07 (-1.99%) ▼|DUK126.34+1.29 (+1.03%) ▲|EMR141.39-1.75 (-1.22%) ▼|FDX316.85-0.39 (-0.12%) ▼|GD344.35-5.99 (-1.71%) ▼|GE365.20+8.73 (+2.45%) ▲|GEV1,056.52+21.54 (+2.08%) ▲|GILD125.25+0.20 (+0.16%) ▲|GM79.28+0.33 (+0.42%) ▲|GOOG344.24-1.84 (-0.53%) ▼|GOOGL344.53-1.56 (-0.45%) ▼|GS1,076.36-18.08 (-1.65%) ▼|HD341.08+16.63 (+5.12%) ▲|HON227.33+4.96 (+2.23%) ▲|IBM263.04-1.90 (-0.72%) ▼|INTC131.03-1.26 (-0.95%) ▼|INTU262.55+4.50 (+1.74%) ▲|ISRG401.41-1.78 (-0.44%) ▼|JNJ241.05+1.97 (+0.82%) ▲|JPM333.83-0.31 (-0.09%) ▼|KO80.65+0.34 (+0.42%) ▲|LIN515.72+3.46 (+0.67%) ▲|LLY1,115.20+8.12 (+0.73%) ▲|LMT493.18-10.49 (-2.08%) ▼|LOW221.52+7.98 (+3.74%) ▲|LRCX372.25+0.92 (+0.25%) ▲|MA494.20+6.13 (+1.26%) ▲|MCD274.30+2.64 (+0.97%) ▲|MDLZ61.69+0.63 (+1.03%) ▲|MDT80.21-0.43 (-0.53%) ▼|META557.91-4.29 (-0.76%) ▼|MMM166.23+4.39 (+2.71%) ▲|MO71.88+0.27 (+0.38%) ▲|MRK120.59+0.99 (+0.83%) ▲|MS220.62-5.41 (-2.39%) ▼|MSFT366.37-7.57 (-2.02%) ▼|MU1,032.03-19.74 (-1.88%) ▼|NEE87.52+1.09 (+1.26%) ▲|NFLX71.90-0.93 (-1.27%) ▼|NKE41.92-0.47 (-1.10%) ▼|NOW94.14-1.80 (-1.88%) ▼|NVDA198.51-1.49 (-0.75%) ▼|ORCL157.40-7.77 (-4.70%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.13-0.59 (-2.39%) ▼|PG151.93+1.07 (+0.71%) ▲|PLTR113.85-2.85 (-2.44%) ▼|PM178.33-0.36 (-0.20%) ▼|QCOM196.42-7.71 (-3.78%) ▼|RTX185.50-0.89 (-0.48%) ▼|SBUX103.81+2.76 (+2.73%) ▲|SCHW91.78-1.39 (-1.49%) ▼|SO95.80+0.87 (+0.92%) ▲|SPG220.74+4.00 (+1.85%) ▲|T22.37-0.45 (-1.95%) ▼|TMO491.66+22.31 (+4.75%) ▲|TMUS181.45-3.12 (-1.69%) ▼|TSLA376.04-5.57 (-1.46%) ▼|TXN302.77-1.59 (-0.52%) ▼|UBER73.93+4.26 (+6.11%) ▲|UNH405.75-3.50 (-0.86%) ▼|UNP260.14+1.53 (+0.59%) ▲|UPS106.08+0.25 (+0.24%) ▲|USB60.21+0.16 (+0.27%) ▲|V332.18+3.70 (+1.13%) ▲|VZ45.76-0.98 (-2.09%) ▼|WFC84.38+0.25 (+0.29%) ▲|WMT119.09-0.33 (-0.28%) ▼|XOM136.68-3.05 (-2.18%) ▼|AAPL294.01-0.29 (-0.10%) ▼|ABBV234.85+0.09 (+0.04%) ▲|ABT90.36-0.18 (-0.19%) ▼|ACN129.29+2.28 (+1.80%) ▲|ADBE197.28-0.15 (-0.08%) ▼|AMAT584.38-1.51 (-0.26%) ▼|AMD516.50-3.35 (-0.64%) ▼|AMGN351.92+4.91 (+1.41%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN234.33+0.22 (+0.09%) ▲|AVGO380.80+0.65 (+0.17%) ▲|AXP343.31+5.53 (+1.64%) ▲|BA220.30+3.59 (+1.66%) ▲|BAC57.84-0.08 (-0.13%) ▼|BKNG180.92+11.98 (+7.09%) ▲|BLK982.66-32.67 (-3.22%) ▼|BMY55.23-0.31 (-0.55%) ▼|BNY143.88-3.41 (-2.32%) ▼|BRK-B495.33+2.52 (+0.51%) ▲|C144.27-0.70 (-0.48%) ▼|CAT992.01+7.77 (+0.79%) ▲|CL91.81+0.38 (+0.42%) ▲|CMCSA22.64-0.17 (-0.72%) ▼|COF200.99+3.18 (+1.61%) ▲|COP107.42-2.56 (-2.32%) ▼|COST960.78+3.10 (+0.32%) ▲|CRM152.74-0.68 (-0.44%) ▼|CSCO119.86-1.29 (-1.06%) ▼|CVS102.32+0.75 (+0.74%) ▲|CVX171.96-4.02 (-2.28%) ▼|DE604.26+12.32 (+2.08%) ▲|DHR188.08+9.11 (+5.09%) ▲|DIS101.47-2.07 (-1.99%) ▼|DUK126.34+1.29 (+1.03%) ▲|EMR141.39-1.75 (-1.22%) ▼|FDX316.85-0.39 (-0.12%) ▼|GD344.35-5.99 (-1.71%) ▼|GE365.20+8.73 (+2.45%) ▲|GEV1,056.52+21.54 (+2.08%) ▲|GILD125.25+0.20 (+0.16%) ▲|GM79.28+0.33 (+0.42%) ▲|GOOG344.24-1.84 (-0.53%) ▼|GOOGL344.53-1.56 (-0.45%) ▼|GS1,076.36-18.08 (-1.65%) ▼|HD341.08+16.63 (+5.12%) ▲|HON227.33+4.96 (+2.23%) ▲|IBM263.04-1.90 (-0.72%) ▼|INTC131.03-1.26 (-0.95%) ▼|INTU262.55+4.50 (+1.74%) ▲|ISRG401.41-1.78 (-0.44%) ▼|JNJ241.05+1.97 (+0.82%) ▲|JPM333.83-0.31 (-0.09%) ▼|KO80.65+0.34 (+0.42%) ▲|LIN515.72+3.46 (+0.67%) ▲|LLY1,115.20+8.12 (+0.73%) ▲|LMT493.18-10.49 (-2.08%) ▼|LOW221.52+7.98 (+3.74%) ▲|LRCX372.25+0.92 (+0.25%) ▲|MA494.20+6.13 (+1.26%) ▲|MCD274.30+2.64 (+0.97%) ▲|MDLZ61.69+0.63 (+1.03%) ▲|MDT80.21-0.43 (-0.53%) ▼|META557.91-4.29 (-0.76%) ▼|MMM166.23+4.39 (+2.71%) ▲|MO71.88+0.27 (+0.38%) ▲|MRK120.59+0.99 (+0.83%) ▲|MS220.62-5.41 (-2.39%) ▼|MSFT366.37-7.57 (-2.02%) ▼|MU1,032.03-19.74 (-1.88%) ▼|NEE87.52+1.09 (+1.26%) ▲|NFLX71.90-0.93 (-1.27%) ▼|NKE41.92-0.47 (-1.10%) ▼|NOW94.14-1.80 (-1.88%) ▼|NVDA198.51-1.49 (-0.75%) ▼|ORCL157.40-7.77 (-4.70%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.13-0.59 (-2.39%) ▼|PG151.93+1.07 (+0.71%) ▲|PLTR113.85-2.85 (-2.44%) ▼|PM178.33-0.36 (-0.20%) ▼|QCOM196.42-7.71 (-3.78%) ▼|RTX185.50-0.89 (-0.48%) ▼|SBUX103.81+2.76 (+2.73%) ▲|SCHW91.78-1.39 (-1.49%) ▼|SO95.80+0.87 (+0.92%) ▲|SPG220.74+4.00 (+1.85%) ▲|T22.37-0.45 (-1.95%) ▼|TMO491.66+22.31 (+4.75%) ▲|TMUS181.45-3.12 (-1.69%) ▼|TSLA376.04-5.57 (-1.46%) ▼|TXN302.77-1.59 (-0.52%) ▼|UBER73.93+4.26 (+6.11%) ▲|UNH405.75-3.50 (-0.86%) ▼|UNP260.14+1.53 (+0.59%) ▲|UPS106.08+0.25 (+0.24%) ▲|USB60.21+0.16 (+0.27%) ▲|V332.18+3.70 (+1.13%) ▲|VZ45.76-0.98 (-2.09%) ▼|WFC84.38+0.25 (+0.29%) ▲|WMT119.09-0.33 (-0.28%) ▼|XOM136.68-3.05 (-2.18%) ▼|
27.5 C
New York
Wednesday, June 24, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1marketreleases

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

BioLab Holdings, Inc. Launches Multicenter Clinical Trial to Evaluate Amnion Grafts for Chronic Wounds

Study Will Assess Real-World Effectiveness of Tri-Layer and Single-Layer Amnion Grafts in Treating Diabetic Foot and Venous Leg Ulcers PHOENIX, July 3, 2025...

Auto Theft Claims Rise in Alberta, Deepening Strain on Insurance Market: IBC Urges Action

EDMONTON, AB, July 3, 2025 /CNW/ - Newly released data from Insurance Bureau of Canada (IBC) shows that the cost of auto theft continued to...

Dr. Hazem Afifi Launches National Scholarship Initiative to Support Undergraduate Medical Students Pursuing Healthcare Careers

LAS VEGAS, July 3, 2025 /PRNewswire/ -- The Dr. Hazem Afifi Scholarship for Medical Students is now officially accepting applications from aspiring healthcare professionals...

Dr. Louis Krenn Medical Scholarship: Empowering Future Leaders in Medicine

SPRINGFIELD, Mo., July 3, 2025 /PRNewswire/ -- The Dr. Louis Krenn Medical Scholarship is now accepting applications from aspiring medical professionals across the United...

Texas Tech, ACU, Natura Resources Announce Path to Deployment for Nuclear Reactor, Desalination of Produced Water

The Texas Legislature positions Texas as a national and global leader in next-generation nuclear technology, water security and medical research  ABILENE, Texas, July 3, 2025...

Quebec implements public reimbursement of Pluvicto® – a defining milestone for radioligand therapy in Canada

Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as...

AAMI Aligns With National Academy of Medicine AI Code of Conduct

AI Code of Conduct’s six core principles key to ensuring the safe and effective use of AI technologies 
AI Code of Conduct’s six core principles key to ensuring the safe and effective use of AI technologies

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

AYR Wellness Provides Update on Receipt of Notice of Disposition of Collateral Relating to PA Natural Medicine LLC and an Extension of the Limited...

MIAMI, July 03, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, today announces that it has received a Notification of Disposition of Collateral (the "Notice") from Anthony J. DePaul, as Agent and Secured Party under the Pledge Agreement dated as of October 1, 2021 between CSAC Acquisition PA II Corp., a subsidiary of the Company, and the Agent (the "Pledge Agreement"). Separately, the Company announces that it has entered into an additional amendment (the “Second Amendment”) to the previously disclosed Limited Waiver Agreement dated June 6, 2025 (the “Original Agreement”), as amended on June 19, 2025 (the “First Amendment”).

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson’s Disease and identifies clear opportunities...

ALTRINCHAM, England, July 3, 2025 /PRNewswire/ -- A new study is the first to examine the application of behavioural science in getting underused therapies...

Fangzhou Tops China’s App Store Chart for Healthcare Apps

GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in...

Innovative Molecules Offer Good News in the Fight Against HIV and Other Viral Infections

INRS team is exploring the potential of saponins, a group of natural molecules found in many plants LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic...

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson’s Disease and identifies clear opportunities...

ALTRINCHAM, England, July 3, 2025 /PRNewswire/ -- A new study is the first to examine the application of behavioural science in getting underused therapies...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers